Fig. 4

Immunofluorescence staining for CD68, TREM-2, CD163, CD206, IL-4 and IL-10 in the biopsy samples. Dual fluorescence staining was done using anti-human CD68 (Alexa 488-Green) and TREM-2, CD163, CD206, IL-4 and IL-10 (Alexa 594-red) antibodies to co-localize CD 68 with TREM-2, CD163, CD206, IL-4 and IL-10 respectively, counterstained with DAPI. Negative controls were run by using isotypes for each fluorochrome. A Immunofluorescence staining in omentum biopsy samples for co-localization of CD68 and TREM-2 (Aa, Ab, Ac), co-localization of CD68 and CD206 (Ad, Ae, Af), co-localization of CD68 and CD163 (Ag, Ah, Ai), co-localization of CD68 and IL-4 (Aj, Ak, Al) and co-localization of CD68 and IL-10 (Am, An, Ao). B Immunofluorescence staining in subcutaneous biopsy samples for co-localization of CD68 and TREM-2 (Ba, Bb, Bc), co-localization of CD68 and CD206 (Bd, Be, Bf), co-localization of CD68 and CD163 (Bg, Bh, Bi), co-localization of CD68 and IL-4 (Bj, Bk, Bl) and co-localization of CD68 and IL-10 (Bm, Bn, Bo). C Immunofluorescence staining in liver biopsy samples for co-localization of CD68 and TREM-2 (Ca, Cb, Cc), co-localization of CD68 and CD206 (Cd, Ce, Cf), co-localization of CD68 and CD163 (Cg, Ch, Ci), co-localization of CD68 and IL-4 (Cj, Ck, Cl) and co-localization of CD68 and IL-10 (Cm, Cn, Co). We found significantly decreased immune reactivity of TREM-2, CD163, CD206, IL-4 and IL-10 in omentum, subcutaneous and liver biopsy samples of obese diabetics compared to obese non-diabetics and non-obese subjects (N = 5 non-obese; 16 obese non-diabetics; 17 obese diabetics)